Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.59 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507121 | 0.83 | ALDH1A1 (0.52) | OGATACR1 | |
| SCHEMBL13535016 | 0.80 | TSHR (0.62) | P2RY12OGA | |
| SCHEMBL5508931 | 0.79 | HDAC6 (0.56) | — | |
| SCHEMBL1618023 | 0.78 | PRMT1 (0.61) | P2RY12OGA | |
| SCHEMBL24881185 | 0.77 | OGA (0.54) | P2RY12OGA | |
| SCHEMBL15038302 | 0.77 | HDAC3 (0.56) | P2RY12OGA | |
| SCHEMBL5506411 | 0.77 | P2RY12 (0.68) | P2RY12 | |
| SCHEMBL6984326 | 0.76 | MAPT (0.57) | P2RY12OGA | |
| SCHEMBL12952642 | 0.76 | POLB (0.54) | P2RY12OGA | |
| SCHEMBL13535033 | 0.76 | MEN1 (0.55) | P2RY12OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8114999-B2 | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8114999-B2 | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2010-02-25 | — | — | US | disclosed |
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2010-02-25 | — | — | US | disclosed |
| US-7501417-B2 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501417-B2 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048588-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | P2RY12 4767/4885OGA 1700/4885TACR1 4549/4885 |
| US-20120108603-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | P2RY12 4767/4885OGA 1700/4885TACR1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.